Your browser doesn't support javascript.
loading
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Amin, Mina; No, Daniel J; Egeberg, Alexander; Wu, Jashin J.
Afiliación
  • Amin M; School of Medicine, University of California, Riverside, CA, USA.
  • No DJ; School of Medicine, Loma Linda University, Loma Linda, CA, USA.
  • Egeberg A; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.
  • Wu JJ; Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, 1515 North Vermont Ave, 5th Floor, Los Angeles, CA, 90027, USA. jashinwu@gmail.com.
Am J Clin Dermatol ; 19(1): 1-13, 2018 Feb.
Article en En | MEDLINE | ID: mdl-29080066
An advanced understanding of the pathogenesis of psoriasis has led to the development of multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor inhibitors, ustekinumab, interleukin-17 inhibitors, and guselkumab (an interleukin-23 inhibitor recently approved for psoriasis) are commercially available biologic agents for psoriasis. Evidence from clinical trials provides pertinent information regarding the safety and efficacy of biologic agents for psoriasis, which should be integrated into clinical decision making. However, disease presentations, disease severity, and comorbid conditions can complicate the choice of initial treatment, which underscores the importance of providing personalized therapy for patients with psoriasis. Furthermore, each biologic agent offers unique benefits and limitations for the treatment of patients with psoriasis. Here, evidence-based recommendations are presented and discussed regarding first-line biologic therapy options for patients with psoriasis and distinct comorbid conditions or patient-related factors. We discuss the comorbid conditions of psoriatic arthritis, multiple sclerosis, congestive heart failure, inflammatory bowel disease, hepatitis B, and latent tuberculosis. Moreover, we describe treatment recommendations for distinct patient populations with psoriasis, including pediatric patients with psoriasis and patients with psoriasis of childbearing potential and nursing.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos / Medicina Basada en la Evidencia / Toma de Decisiones Clínicas Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Am J Clin Dermatol Asunto de la revista: DERMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos / Medicina Basada en la Evidencia / Toma de Decisiones Clínicas Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Am J Clin Dermatol Asunto de la revista: DERMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda